KTTA

Pasithea Therapeutics Corp.

Insider Trades

NameValueActionPriceCurrent Price
Coastlands Capital LP10 Percent Owner
$53k100k shares
BuyJun 17, 2026
$0.53
$0.5389
Marques TiagoDirector, Officer: Chief Executive Officer
$792960 shares
SellMay 12, 2025
$0.825
--
Dumesnil SimonDirector
$25k33.3k shares
BuyNov 28, 2025
$0.75
--
Marques TiagoDirector, Officer: Chief Executive Officer
$25k33.3k shares
BuyNov 28, 2025
$0.75
--
Steinman LawrenceDirector
$100k133.3k shares
BuyNov 28, 2025
$0.75
--

News

globenewswire.comPasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trialglobenewswire.comJun 16globenewswire.comPasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conferenceglobenewswire.comJun 15zacks.comPasithea Therapeutics (KTTA) Could Find a Support Soon, Here's Why You Should Buy the Stock Nowzacks.comJun 10globenewswire.comPasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)globenewswire.comJun 2globenewswire.comPasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officerglobenewswire.comMay 4